Tourmaline Bio (TRML) Expected to Announce Quarterly Earnings on Monday

Tourmaline Bio (NASDAQ:TRML) is projected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.91) per share for the quarter.

Tourmaline Bio (NASDAQ:TRML) last released its quarterly earnings data on Friday, May 2nd. The company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.02. On average, analysts expect Tourmaline Bio to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Tourmaline Bio Price Performance

Shares of TRML stock opened at $15.09 on Friday. The stock has a market cap of $387.59 million, a P/E ratio of -5.35 and a beta of 2.11. The stock has a fifty day moving average price of $15.49 and a 200 day moving average price of $18.78. Tourmaline Bio has a one year low of $11.56 and a one year high of $29.79.

Analyst Ratings Changes

TRML has been the topic of a number of analyst reports. Lifesci Capital assumed coverage on shares of Tourmaline Bio in a research note on Monday, February 24th. They issued an “outperform” rating and a $58.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Tourmaline Bio in a research note on Monday, May 5th. Chardan Capital reissued a “buy” rating and issued a $70.00 target price on shares of Tourmaline Bio in a report on Monday, May 5th. Finally, Wedbush boosted their price target on Tourmaline Bio from $42.00 to $43.00 and gave the company an “outperform” rating in a research note on Friday, March 14th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Tourmaline Bio currently has a consensus rating of “Buy” and a consensus price target of $49.33.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.